Old Web
English
Sign In
Acemap
>
authorDetail
>
Jesper Jernelius
Jesper Jernelius
Placebo
Transthyretin
Pharmacodynamics
Dosing
Tolerability
2
Papers
18
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
First‐in‐Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers
2019
Clinical pharmacology in drug development
Jonathan C. Fox
Jennifer L. Hellawell
Satish Rao
Terry O'Reilly
Rick Lumpkin
Jesper Jernelius
Daniel D. Gretler
Uma Sinha
Show All
Source
Cite
Save
Citations (15)
AG10, A Novel, Potent and Selective Transthyretin Stabilizer, is Well Tolerated at Doses Resulting in Target Therapeutic Blood Levels, and Demonstrates Clinical Proof-of-Concept in Healthy Volunteers
2018
Journal of Cardiac Failure
Jennifer L Hellawell
Satish Rao
Terry O'Reilly
Rick Lumpkin
Jesper Jernelius
Daniel D. Gretler
Uma Sinha
Jonathan C. Fox
Show All
Source
Cite
Save
Citations (3)
1